Low-dose atropine data, secondary dry eye disease pearls top Healio’s AAO 2023 coverage
Click Here to Manage Email Alerts
Healio’s top items from this year’s American Academy of Ophthalmology meeting included pearls for navigating secondary dry eye disease as well as data for low-dose atropine as a myopia treatment in children aged 3 to 17 years.
Check out these items and more below.
Speaker offers tips for navigating secondary dry eye disease
Dry eye is an umbrella term that covers multiple etiologies and different presentations.
“As a community, we need to come up with some terminology that we can all agree on that is going to help our patients,” Anat Galor, MD, said during Cornea Subspecialty Day at the American Academy of Ophthalmology meeting. Read more.
Low-dose atropine slows myopia progression in children aged 3 to 17 years
A low-dose, preservative-free formulation of atropine is effective in slowing myopia progression in children aged 3 to 17 years, according to phase 3 data. Read more.
AI preassessment calls may streamline clinics
A phone preassessment using artificial intelligence showed potential for streamlining clinics, according to a study. Read more.
VIDEO: Sozinibercept in ‘last push’ of phase 3 clinical development
In this Healio Video Perspective from Eyecelerator@AAO, Megan Baldwin, PhD, of Opthea shares an update on sozinibercept, a VEGF-C/D inhibitor for the treatment of neovascular age-related macular degeneration. Read more.
VIDEO: Avacincaptad pegol shows positive GA reduction, safety profile at 2 years
In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Arshad Khanani, MD, MA, FASRS, discusses 2-year results of the GATHER2 trial investigating avacincaptad pegol for geographic atrophy. Read more.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts